H7N9 Influenza
5
0
0
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
20 treatments under study, led by 15μg H7n9 Vaccine
Research Leaders
6 sponsors active, led by Shanghai Institute Of Biological Products
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 5 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (5)
Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)
A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine
A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine
Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
Research Network
Common Treatments
- 15μg H7n9 Vaccine2
- Aluminum Hydroxide2
- H7n9c Medium Dose With Adjuvant1
- 75μg H7n9 Vaccine1
- Phosphate Buffer Solution1
Active Sponsors
- Shanghai Institute Of Biological Products2
- Henan Center for Disease Control and Prevention1
- Butantan Institute1
- Biomedical Advanced Research and Development Authority1
- Vaxxas Pty Ltd1
Top Investigators
University of Sao Paulo
Henan Center for Disease Control and Prevention
Novartis Vaccines
Shanghai Institute Of Biological Products
Related Conditions
- Influenza1